Welireg®
Active substance | Belzutifan | ||||||||||||||||
Holder | MSD Belgium BV/SRL | ||||||||||||||||
Status | Running | ||||||||||||||||
Indication | Belzutifan (Welireg®) is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated, localized renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for w
Vyvgart
|